A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy.
This meta-analysis aimed to evaluate whether an association exists between the ERCC1 rs11615 (C>T) polymorphism and patient response to platinum-based chemotherapy and radiation-based chemotherapy.



Publications were selected from PubMed and MEDLINE. A meta-analysis was conducted to determine the association between genetic polymorphisms and response to platinum-based chemotherapy and radiation-based chemotherapy by checking the odds ratios (ORs) and 95 % confidence intervals (CIs).



In our overall analysis, the ERCC1 rs11615 (C>T) polymorphism was not associated with response to platinum-based chemotherapy in five comparison models. In the subgroup analyses by ethnicity, the ERCC1 rs11615 (C>T) polymorphism was shown to be significantly associated with objective response in Caucasian patients treated with platinum-based chemotherapy in the recessive model (TT vs.



OR 0.696, 95 % CI 0.508-0.954, heterogeneity = 0.330), but the association was not observed in the Asian population. The C allele was significantly associated with better response to radiochemotherapy in the recessive model comparison (TT vs.



OR 0.724, 95 % CI 0.585-0.869, heterogeneity = 0.008). Subgroup analysis by cancer type revealed that the C allele of ERCC1 rs11615 predicted a better response in esophageal cancers in two comparison models (T vs. C: OR 0.756, 95 % CI 0.648-0.880, heterogeneity = 0.653; TT vs.



OR 0.457, 95 % CI 0.306-0.684, heterogeneity = 0.723). Stratified analysis by ethnicity showed a better response in Caucasians in allelic comparison model (T vs. C: OR 0.895, 95 % CI 0.819-0.977, heterogeneity = 0.095).



Together, our results suggest that the ERCC1 rs11615 (C>T) polymorphism was associated with therapeutic response in Caucasian patients and C allele of ERCC1 rs11615 could represent a genetic molecular marker to predict better patient response to radiochemotherapy in recessive model. However, larger prospective randomized trials will be required.
Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 Qing-chun East Road, Hangzhou, 310016, People's Republic of China.
Fengying
F
Li
Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 Qing-chun East Road, Hangzhou, 310016, People's Republic of China.
Xinyou
X
Xie
Department of Prevention and Control of Infectious Diseases, Hangzhou Municipal Center for Disease Control and Prevention, 568 Mingshi Road, Hangzhou, 310021, People's Republic of China. xiaobinren80@126.com.
Xiaobin
X
Ren
Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 Qing-chun East Road, Hangzhou, 310016, People's Republic of China. jameszhang2000@sohu.com.
Jun
J
Zhang
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D059248:Chemoradiotherapy / Q000379:methods*; D004268:DNA-Binding Proteins / Q000235:genetics*; D004720:Endonucleases / Q000235:genetics*; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D016017:Odds Ratio; D010984:Platinum / Q000008:administration & dosage / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D016896:Treatment Outcome; D044465:White People / Q000235:genetics*
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D005819:Genetic Markers; D010984:Platinum; C071447:ERCC1 protein, human; D004720:Endonucleases
ERCC1; Meta-analysis; Platinum-based chemotherapy; Polymorphism; Radiochemotherapy